Open Access

RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma

  • Authors:
    • Yuenan Liu
    • Gong Cheng
    • Zhengshuai Song
    • Tianbo Xu
    • Hailong Ruan
    • Qi Cao
    • Keshan Wang
    • Lin Bao
    • Jingchong Liu
    • Lijie Zhou
    • Di Liu
    • Hongmei Yang
    • Ke Chen
    • Xiaoping Zhang
  • View Affiliations

  • Published online on: July 26, 2019     https://doi.org/10.3892/ijo.2019.4849
  • Pages: 645-656
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

As one of the most commonly reported malignancies of the urinary system, clear cell renal cell carcinoma (ccRCC) is an advanced metastatic tumor with high mortality rates. The Rac family small GTPase 2 (RAC2) is a member of the Rho GTPases. Although Rho GTPases play an important role in numerous different types of tumor, whether they have functions in ccRCC remains uncertain. The present study utilized bioinformatics analyses in order to compare the expression levels of RAC2 in ccRCC tumors vs. adjacent tissues, and assessed the association between RAC2 expression and clinicopathological parameters. Furthermore, reverse transcription‑quantitative PCR, western blotting and immunohistochemistry assays were performed to validate RAC2 expression levels in human ccRCC tissues and cell lines. Functional experiments were also conducted in order to identify the roles of RAC2 in vitro. The results revealed that RAC2 was upregulated in ccRCC tissues and cell lines. In addition, elevated expression levels of RAC2 were significantly associated with a poor overall survival (P=0.0061), higher Tumor‑Node‑Metastasis stage and worse G grade. Receiver operating characteristic analysis indicated that high expression levels of RAC2 could be a diagnostic index for ccRCC (area under the curve, 0.9095; P<0.0001). Furthermore, knockdown of RAC2 in vitro attenuated the proliferation, migration and invasion of renal carcinoma cells. In conclusion, the results of the present study demonstrated that RAC2 may act as a promising prognostic and diagnostic biomarker of ccRCC, and could be considered as a potential therapeutic target for treating ccRCC.
View Figures
View References

Related Articles

Journal Cover

September 2019
Volume 55 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, Y., Cheng, G., Song, Z., Xu, T., Ruan, H., Cao, Q. ... Zhang, X. (2019). RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma. International Journal of Oncology, 55, 645-656. https://doi.org/10.3892/ijo.2019.4849
MLA
Liu, Y., Cheng, G., Song, Z., Xu, T., Ruan, H., Cao, Q., Wang, K., Bao, L., Liu, J., Zhou, L., Liu, D., Yang, H., Chen, K., Zhang, X."RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma". International Journal of Oncology 55.3 (2019): 645-656.
Chicago
Liu, Y., Cheng, G., Song, Z., Xu, T., Ruan, H., Cao, Q., Wang, K., Bao, L., Liu, J., Zhou, L., Liu, D., Yang, H., Chen, K., Zhang, X."RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma". International Journal of Oncology 55, no. 3 (2019): 645-656. https://doi.org/10.3892/ijo.2019.4849